

## Special Issue

# Mantle Cell Lymphoma: From Biology to Therapy

### Message from the Guest Editor

Mantle cell lymphoma (MCL) is a heterogeneous disease comprising around 2.5–6% of B-cell non-Hodgkin lymphoma cases. The primary genetic alteration in MCL is chromosomal translocation (11;14) which leads to CyclinD1 overexpression and uncontrolled cell proliferation. There are several variants of MCL including leukemic non-nodal, classic, blastoid, and pleomorphic, which have varying biological characteristics that lead to different disease courses and long-term outcomes. The survival of patients with MCL has significantly improved over the past decade due to better understanding of the disease biology and the advent of targeted therapies. Small-molecule inhibitors such as proteasome inhibitors, immunomodulators, BTK inhibitors, and BCL2 inhibitors either alone or in combination have changed the treatment landscape and outcomes regarding this disease. In this issue, we will focus on the advancements made in the field of MCL starting with biology and discussing the current and emerging therapies in light of these advancements.

### Guest Editor

Dr. Narendranath Epperla

The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA

### Deadline for manuscript submissions

closed (25 December 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/133931](https://mdpi.com/si/133931)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)